| Karl E Magsamen, MD | |
|
1024 S Lemay Ave, Fort Collins, CO 80524-3929 | |
| (970) 495-7000 | |
| (970) 495-7639 |
| Full Name | Karl E Magsamen |
|---|---|
| Gender | Male |
| Speciality | Interventional Radiology |
| Experience | 26 Years |
| Location | 1024 S Lemay Ave, Fort Collins, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033202536 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mclaren Northern Michigan | Petoskey, MI | Hospital |
| Brookdale Hospital Medical Center | Brooklyn, NY | Hospital |
| University Medical Center | Lubbock, TX | Hospital |
| Longs Peak Hospital | Longmont, CO | Hospital |
| Medical Center Of The Rockies | Loveland, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| On-line Radiology Medical Group Inc | 0648311548 | 49 |
| Radiology Associates Of Albuquerque Pa | 2860304482 | 77 |
| Kent Diagnostic Radiology Associates Pa | 3971591371 | 46 |
| Lansing Radiology Associates P C | 4486552148 | 52 |
| Pco Pc | 5395179329 | 56 |
| Uchealth Imaging Services Llc | 5799021291 | 141 |
| Yampa Valley Medical Center | 5890685689 | 122 |
| Freeport Memorial Hospital | 8426958232 | 105 |
| Brookdale Hospital Medical Center | 4284545799 | 279 |
| Dhew Ind Hlth Sv Hlth Svs And Mntl Hlth Adm | 1759290901 | 173 |
| University Medical Center Radiology | 4385538941 | 49 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | Yampa Valley Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790787307 PECOS PAC ID: 5890685689 Enrollment ID: O20040316001301 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | Poudre Valley Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366763260 PECOS PAC ID: 9638208549 Enrollment ID: O20100602000122 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | Uchealth Imaging Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396210902 PECOS PAC ID: 5799021291 Enrollment ID: O20190103002022 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | Kent Diagnostic Radiology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417044298 PECOS PAC ID: 3971591371 Enrollment ID: O20190906000062 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | Radiology Associates Of Albuquerque Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881666998 PECOS PAC ID: 2860304482 Enrollment ID: O20190926002793 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | Pco Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881230563 PECOS PAC ID: 5395179329 Enrollment ID: O20200806001480 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | On-line Radiology Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710158498 PECOS PAC ID: 0648311548 Enrollment ID: O20201002002241 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | Central Valley Community Medical Imaging |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376637264 PECOS PAC ID: 5799679874 Enrollment ID: O20211116001921 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | Freeport Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447228788 PECOS PAC ID: 8426958232 Enrollment ID: O20220828000008 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | Camelot Radiology Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841244753 PECOS PAC ID: 4880580521 Enrollment ID: O20220913003571 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | East Central Illinois Radiology Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912277443 PECOS PAC ID: 3870750482 Enrollment ID: O20221222002197 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | Lansing Radiology Associates P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669425658 PECOS PAC ID: 4486552148 Enrollment ID: O20230124003578 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | Radiology Associates Of South Carolina Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083491906 PECOS PAC ID: 3779932959 Enrollment ID: O20240218000049 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Entity Name | Bayhealth Radiologists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366214124 PECOS PAC ID: 0446601876 Enrollment ID: O20240304000465 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karl E Magsamen, MD 2008 Caribou Dr, Fort Collins, CO 80525-4325 Ph: (970) 484-4757 | Karl E Magsamen, MD 1024 S Lemay Ave, Fort Collins, CO 80524-3929 Ph: (970) 495-7000 |
News Archive
Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.
A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity.
Australian drug discovery company Bionomics Limited today updated shareholders at its Annual General Meeting on the recent progress of its anti-cancer drug BNC105 and drug discovery programs in anxiety and Multiple Sclerosis.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Pharmaceutical companies and diagnostics companies spend billions developing new drugs and tests, and this is translating into a sizeable market for the instruments that can assist them. This according to Kalorama Information, a healthcare market research publisher. Kalorama Information said instruments such as mass spectrometry, electrophoresis and liquid chromatography that can assist in the identification of drug targets and the validation of biomarkers, are in demand.
› Verified 4 days ago
Dr. Tracy Haefele Florant, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 430 Spinnaker Ln, Fort Collins, CO 80525 Phone: 970-988-8637 | |
Dr. Karen B Alderfer, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 | |
Dr. Nathan Miller, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 | |
Dr. Kevin Limbaugh, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-8600 Fax: 970-495-7619 | |
Dr. Guy Thomas Alexander, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 | |
Dr. Audrey Marie Magnowski, MD Radiology Medicare: Medicare Enrolled Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 |